<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04696185</url>
  </required_header>
  <id_info>
    <org_study_id>SEC-DAPATAVI-2020</org_study_id>
    <nct_id>NCT04696185</nct_id>
  </id_info>
  <brief_title>Dapagliflozin After Transcatheter Aortic Valve Implantation</brief_title>
  <acronym>DapaTAVI</acronym>
  <official_title>Dapagliflozin After Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Society of Cardiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Society of Cardiology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pragmatic, controlled, prospective, randomized, open-label (open-label), evaluator-blind&#xD;
      clinical trial (PROBE design) that will analyze the benefits of dapagliflozin treatment in&#xD;
      patients with severe aortic stenosis discharged after implantation of an aortic valve&#xD;
      prosthesis transcatheter (TAVI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients discharged after TAVI, with a history of heart failure (HF) plus depressed left&#xD;
      ventricular ejection fraction (LVEF ≤ 40%) or diabetes mellitus (DM) or glomerular filtration&#xD;
      rate (GFR) between 25 and 75 ml/min/1.73 m2, will be randomized (1:1) before hospital&#xD;
      discharge to receive treatment with dapagliflozin 10 mg/day or no dapagliflozin (no placebo).&#xD;
&#xD;
      Only variables available during routine clinical practice will be collected and there will be&#xD;
      no additional tests.&#xD;
&#xD;
      The incidence of clinical events and adherence to the dapagliflozin arm will be documented at&#xD;
      2 time-points (3 ± 1 months and 12 months) by phone calls and review of medical records.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Dapa-TAVI is a pragmatic, controlled, prospective, randomized, open-label blinded endpoint (PROBE design) clinical trial. Patients being discharged after TAVI who meet all inclusion criteria, and none of the exclusion criteria, will be eligible for the enrollment. Patients will be 1:1 randomized to 1 of these 2 arms:&#xD;
Intervention group: Sodium-glucose cotransporter-2 (SGLT-2) inhibitor therapy with daily oral dose of dapagliflozin 10 mg.&#xD;
Control group: no SGLT-2 inhibitor therapy with dapagliflozin.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>All events will be adjudicated by the Clinical Events Adjudication Committee (CEAC), without information about the therapy (intervention or control) (blinded endpoint)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of the composite of all-cause mortality or worsening heart failure (HF)</measure>
    <time_frame>1 year</time_frame>
    <description>All-cause mortality and worsening HF (including hospitalization for HF or an urgent visit resulting in intravenous therapy for HF).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence rate all-cause mortality</measure>
    <time_frame>1 year</time_frame>
    <description>All cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of Cardiovascular death</measure>
    <time_frame>1 year</time_frame>
    <description>Mortality secondary to cardiovascular cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of worsening heart failure (HF)</measure>
    <time_frame>1 year</time_frame>
    <description>Worsening HF (including hospitalization for HF or an urgent visit resulting in intravenous therapy for HF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of atrial fibrillation</measure>
    <time_frame>1 year</time_frame>
    <description>Atrial Fibrillation confirmed by ECG</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Improvement in NYHA class.</measure>
    <time_frame>1 year</time_frame>
    <description>Functional class according to New York Heart Association classification</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety endpoints</measure>
    <time_frame>1 year</time_frame>
    <description>Symptomatic hypotension. Symptomatic hypotension includes postural dizziness with systolic blood pressure &lt; 100 mmHg, and orthostatic hypotension (defined as a decrease of &gt;20 mmHg in systolic blood pressure or &gt;10 mmHg in diastolic blood pressure from a supine to a standing position).&#xD;
Major hypoglycemia. Major hypoglucemia is defined as an event where all the following criteria were confirmed by the investigator: (1) the patient experienced symptoms of severe impairment in consciousness or behaviour; (2) the patient needed external assistance; (3) intervention was needed to treat the hypoglycaemia; and (4) there was prompt recovery of acute symptoms following the intervention.&#xD;
Ketoacidosis.&#xD;
Genital or Urinary Infections&#xD;
Amputation&#xD;
Necrotizing Fasciitis of the Perineum (Fournier's Gangrene)</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of treatment switch (crossovers)</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of patients in the &quot;dapagliflozin arm&quot; who stop this treatment and percentage of patients in &quot;standard care&quot; arm who start dapagliflozin therapy</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1020</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Transcatether Aortic Valve Implantation</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium-glucose cotransporter-2 (SGLT-2) inhibitor therapy with daily oral dose of dapagliflozin 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No SGLT-2 inhibitor therapy with dapagliflozin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10 MG</intervention_name>
    <description>Dapagliflozin 10 mg (daily oral dose)</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  SEVERE AORTIC STENOSIS UNDERWENT TAVI&#xD;
&#xD;
          -  PRIOR HEART FAILURE ADMISSION AND ONE OF THE FOLLOWING CRITERIA:&#xD;
&#xD;
               1. Left ventricular ejection fraction ≤ 40% or&#xD;
&#xD;
               2. Diabetes mellitus or&#xD;
&#xD;
               3. Estimated glomerular filtrate rate 25-75 ml/min/1.73 m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy or intolerance to SGLT2 inhibitors.&#xD;
&#xD;
          -  Concomitant therapy with sulfonylurea or SGLT2 inhibitors..&#xD;
&#xD;
          -  Systolic blood pressure &lt; 100 mmHg or diastolic blood pressure &lt; 50 mmHg.&#xD;
&#xD;
          -  An estimated glomerular filtration rate (GFR) below 25 ml per minute per 1.73 m2.&#xD;
&#xD;
          -  Chronic cystitis and/or recurrent urinary tract infections (2 or more in the last&#xD;
             year)&#xD;
&#xD;
          -  Poor control of diabetes mellitus that requires SGLT-2 inhibitor prescription on&#xD;
             discharge according to treating physician judge.&#xD;
&#xD;
          -  Any medical condition that, in the investigator´s judgment, would seriously limit life&#xD;
             expectancy (less than one year).&#xD;
&#xD;
          -  Pregnant or breast-feeding patients&#xD;
&#xD;
          -  Patients participating in other clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>EMAD ABU ASSI, PhD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Alvaro Cunqueiro, Vigo, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BORJA IBAÑEZ, PhD, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centro Nacional de Investigaciones Cardiovasculares (CNIC, Madrid, Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>SERGIO RAPOSEIRAS ROUBIN, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Alvaro Cunqueiro, Vigo, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>IGANCIO AMAT SANTOS, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario de Valladolid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SERGIO RAPOSEIRAS ROUBIN, PhD, MD</last_name>
    <phone>034 620170387</phone>
    <email>raposeiras26@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>IGNACIO AMAT SANTOS, PhD, MD</last_name>
    <phone>034 657923040</phone>
    <email>ijamat@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario de Albacete</name>
      <address>
        <city>Albacete</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital German I Trias</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Vilalta del Olmo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta Del Mar</name>
      <address>
        <city>Cadiz</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Livia Gheorge</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MANUEL PAN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de Las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Ramón Jiménez</name>
      <address>
        <city>Huelva</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Francisco Díaz Fernández</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de La Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ANTONIO MUÑOZ</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesar Moris</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valeriano Ruiz Quevedo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SERGIO GARCÍA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Ten Morro</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://www.dapatavi.com/</url>
    <description>Web Page of DapaTAVI trial</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 30, 2020</study_first_submitted>
  <study_first_submitted_qc>January 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spanish Society of Cardiology</investigator_affiliation>
    <investigator_full_name>SERGIO RAPOSEIRAS ROUBIN</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Aortic Stenosis</keyword>
  <keyword>TAVI</keyword>
  <keyword>Dapagliflozin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data will be available to other researchers after ending the trial, prior to a formal request to the Executive Committee</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>5 years</ipd_time_frame>
    <ipd_access_criteria>Email (dapatavi@gmail.com)</ipd_access_criteria>
    <ipd_url>https://www.dapatavi.com/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT04696185/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT04696185/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

